Drug Trial Radar · NCT03976401
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
May 28, 2019
Primary completion
Feb 10, 2021
Study completion Jan 10, 2022
Sponsor
- Lead sponsor
- Akero Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
EFXDrug
Administered by subcutaneous injection
PlaceboDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12.Time frame: 12 weeks
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Akero Clinical Study Site
Tucson, Arizona
Akero Clinical Study Site
Little Rock, Arkansas
Akero Clinical Study Site
Huntington Park, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Los Angeles, California
Akero Clinical Study Site
Panorama City, California
Akero Clinical Study Site
Poway, California
Akero Clinical Study Site
Boca Raton, Florida
Akero Clinical Study Site
Lakewood Rch, Florida
Akero Clinical Study Site
Miami, Florida
Akero Clinical Study Site
New Port Richey, Florida
Akero Clinical Study Site
Ocoee, Florida
Akero Clinical Study Site
Port Orange, Florida
Akero Clinical Study Site
Sarasota, Florida
Akero Clinical Study Site
Baton Rouge, Louisiana
Akero Clinical Study Site
Marrero, Louisiana
Akero Clinical Study Site
Kansas City, Missouri
Akero Clinical Study Site
Berlin, New Jersey
Akero Clinical Study Site
Chattanooga, Tennessee
Akero Clinical Study Site
Cedar Park, Texas
Akero Clinical Study Site
Dallas, Texas
Akero Clinical Study Site
Edinburg, Texas
Akero Clinical Study Site
Fort Worth, Texas
Akero Clinical Study Site
San Antonio, Texas
Akero Clinical Study Site
San Antonio, Texas
Akero Clinical Study Site
Webster, Texas
Akero Clinical Study Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.